2026· Pharmaceutical Sciences Asia· Vol 53, pp. 247-264· 0 citations
TL;DR
Major nanocarrier platforms are examined, with particular emphasis on their tunable physicochemical properties and modular architectures that facilitate adaptation to diverse patient populations, including elderly patients and those with treatment-resistant conditions.
Abstract
Multifunctional nanocarriers have emerged as a transformative approach in cancer therapy by overcoming traditional limitations such as systemic toxicity, poor tumor selectivity, and multidrug resistance. This review highlights recent advances in the design and application of customizable nanocarrier systems that integrate targeting, imaging, and combination drug delivery for more personalized and population-specific treatments. We examine major nanocarrier platforms, including lipid-based, polymeric, inorganic, and hybrid systems, with particular emphasis on their tunable physicochemical properties and modular architectures that facilitate adaptation to diverse patient populations, including elderly patients and those with treatment-resistant conditions. Functionalization strategies, such as ligand-mediated targeting and stimuli-responsive release, are discussed in the context of improving site-specific delivery and minimizing off-target effects. The integration of imaging agents enables theranostic functionality for real-time treatment monitoring. We also explore co-delivery systems for synergistic therapies combining chemotherapy, immunomodulation, and phototherapy. Clinical progress, regulatory challenges, and future trends including AI-driven design and bioinspired materials are discussed. This review underscores the pivotal role of multifunctional nanocarriers in advancing precision and inclusive oncology.
Nanocarriers have revolutionized the field of targeted drug delivery in cancer therapy, offering
enhanced specificity and reduced side effects compared to traditional treatments. These nanoscale
delivery systems, including liposomes, dendrimers, and polymeric nanoparticles, are engineered
to deliver chemotherapeutic ag...
Busayo Olamide Tomoh· International Journal of Med...· 0 citations
In recent times, permeation of nanotechnology to modern medicine has revolutionized transformation, especially in the case of cancer diagnosis and therapy, positioning nanomedicine as a key pillar of next-generation healthcare. Tuning the physicochemical properties of nanoparticles such as size, morphology, and surface...
Biswajit Mohanty, P. Saikia, Piyush Pandey et al.· Frontiers in Chemistry· 0 citations
Breast cancer remains a major global health concern, highlighting the need for advanced drug delivery strategies that can improve therapeutic efficacy while minimizing systemic toxicity. Although several reviews have discussed polymeric nanocarriers for breast cancer therapy, many have primarily focused on specific p...
Nazanin Amiryaghoubi, B. Kim· ACS Applied Nano Materials· 0 citations
Cancer remains a major global health challenge, accounting for substantial morbidity and mortality despite advances in surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapies. However, the clinical effectiveness of these treatments is frequently limited by poor drug specificity, systemic toxicity, mu...
Aliya Rehmani, Palak Ghanshyam Rahangdale, Payal Dilip Meshram· Journal of Drug Delivery and...· 0 citations
Current preclinical evidence supports nanomedicine as a central pillar of precision drug delivery, with future progress expected to focus on adaptive, multifunctional, and patient-specific platforms that align with the principles of personalized medicine.
Ashna Sureshkumar, Prakash Balu· Frontiers in Biomaterials Sc...· 0 citations
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype lacking effective targeted therapies. Its tumor microenvironment (TME) exhibits distinct features, including acidity, redox imbalance, elevated reactive oxygen species (ROS), and hypoxia, which provide exploitable triggers for targeted drug...
Adnan Murad Bhayo, Ying Li, Alaa R. Aboushanab et al.· Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.